Burns Matteson Capital Management LLC Buys Shares of 3,919 Biogen Inc. $BIIB

Burns Matteson Capital Management LLC bought a new position in Biogen Inc. (NASDAQ:BIIB) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 3,919 shares of the biotechnology company’s stock, valued at approximately $690,000.

Several other institutional investors have also recently made changes to their positions in the company. State Street Corp raised its holdings in shares of Biogen by 1.0% in the second quarter. State Street Corp now owns 7,468,807 shares of the biotechnology company’s stock valued at $938,007,000 after acquiring an additional 71,897 shares in the last quarter. Invesco Ltd. grew its holdings in Biogen by 4.2% during the 3rd quarter. Invesco Ltd. now owns 2,418,127 shares of the biotechnology company’s stock worth $338,731,000 after acquiring an additional 98,001 shares in the last quarter. AQR Capital Management LLC increased its position in Biogen by 30.7% during the 3rd quarter. AQR Capital Management LLC now owns 1,783,581 shares of the biotechnology company’s stock valued at $248,809,000 after purchasing an additional 418,776 shares during the period. Legal & General Group Plc raised its holdings in shares of Biogen by 10.1% in the 3rd quarter. Legal & General Group Plc now owns 1,593,399 shares of the biotechnology company’s stock valued at $223,203,000 after purchasing an additional 146,583 shares in the last quarter. Finally, Pacer Advisors Inc. raised its holdings in shares of Biogen by 9.9% in the 3rd quarter. Pacer Advisors Inc. now owns 1,451,249 shares of the biotechnology company’s stock valued at $203,291,000 after purchasing an additional 131,258 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Trading Down 2.3%

NASDAQ BIIB opened at $183.33 on Wednesday. Biogen Inc. has a 52 week low of $110.04 and a 52 week high of $202.41. The company has a 50 day moving average price of $186.19 and a 200 day moving average price of $170.98. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34. The firm has a market cap of $26.91 billion, a PE ratio of 20.81, a price-to-earnings-growth ratio of 1.49 and a beta of 0.15.

Biogen (NASDAQ:BIIB) last announced its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, beating the consensus estimate of $1.61 by $0.38. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The company had revenue of $2.28 billion during the quarter, compared to the consensus estimate of $2.21 billion. During the same period last year, the firm earned $3.44 earnings per share. Biogen’s revenue was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, sell-side analysts forecast that Biogen Inc. will post 15.83 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on BIIB shares. HSBC increased their price objective on shares of Biogen from $143.00 to $150.00 and gave the company a “reduce” rating in a research note on Tuesday, March 17th. Piper Sandler upped their target price on Biogen from $157.00 to $177.00 and gave the stock a “neutral” rating in a report on Monday, February 9th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Biogen in a research report on Monday, December 29th. Tudor Pickering set a $201.00 price target on Biogen in a report on Monday, February 9th. Finally, Wedbush boosted their price target on Biogen from $178.00 to $187.00 and gave the stock a “neutral” rating in a research report on Monday, February 9th. Twelve investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Biogen currently has an average rating of “Hold” and an average price target of $205.31.

Trending Headlines about Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: FDA approves a higher‑dose regimen of SPINRAZA, which could bolster Biogen’s rare‑disease revenue and defend market share in spinal muscular atrophy; the approval was cited as a catalyst for an earlier share pop. US FDA approves higher-dose of Biogen’s genetic disorder drug
• Positive Sentiment: Biogen agreed to buy Apellis for about $5.6B, gaining commercial drugs (EMPAVELI®, SYFOVRE®) and entry into nephrology and ophthalmology — a strategic move to diversify beyond MS and lift long‑term growth expectations. Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio
• Neutral Sentiment: Analysts largely kept Hold/neutral ratings after the news — firms note the approvals and deal are constructive but that execution, MS franchise erosion and competition limit near‑term upside. Spinraza HD approval supports but does not transform outlook
• Negative Sentiment: Market reaction is mixed-to-negative for BIIB: Apellis stock more than doubled on the buyout (market sees strong value in Apellis), while Biogen shares fell as investors weigh the $5.6B cash outlay, premium paid and contingent CVR payments. Apellis Pharma Skyrockets on Biogen Deal
• Negative Sentiment: Integration and financial risk: analysts and commentary flag potential near‑term pressure on cash and the need to execute launches and cross‑sell acquired products; some view the price as a premium that constrains near‑term EPS benefit. Biogen Acquires Apellis: Synergies, Risks, And What The Market Is Missing

Insider Buying and Selling at Biogen

In other news, insider Priya Singhal sold 2,660 shares of the firm’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the sale, the insider owned 8,043 shares of the company’s stock, valued at $1,607,232.69. This trade represents a 24.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.18% of the stock is owned by insiders.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.